[{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ BAUSCH + LOMB","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ BAUSCH + LOMB"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Clearside Biomedical","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Clearside Biomedical"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch + Lomb","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch + Lomb"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":2.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":2.5,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Macrogol","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.11,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":2.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":2.5,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch & Lomb Incorporated \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Eyenovia"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lutein","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":null,"graph2":null,"graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":null,"companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":null,"graph2":null,"graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":null,"companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":null,"graph2":null,"graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":null,"companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"}]

Find Clinical Drug Pipeline Developments & Deals by Bausch & Lomb Incorporated

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Blink NutriTears is a clinically proven nutritional supplement developed to help relieve dry eye symptoms. It contains a proprietary blend of lutein, zeaxanthin, curcumin, & vitamin D.

                          Brand Name : Blink NutriTears

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 03, 2024

                          Lead Product(s) : Lutein,Zeaxanthin,Curcumin

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Eyenovia re-acquired rights to MicroPine in the U.S. and Canada, expanding its phase III pipeline, being evaluated as a potential treatment for pediatric progressive myopia.

                          Brand Name : MicroPine

                          Molecule Type : Small molecule

                          Upfront Cash : $5.0 million

                          January 16, 2024

                          Lead Product(s) : Atropine

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Eyenovia

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...

                          Brand Name : Xiidra

                          Molecule Type : Small molecule

                          Upfront Cash : $1,750.0 million

                          September 29, 2023

                          Lead Product(s) : Lifitegrast

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Recipient : Novartis Pharmaceuticals Corporation

                          Deal Size : $2,500.0 million

                          Deal Type : Divestment

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : MIEBO (perfluorohexyloctane ophthalmic solution) is used for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.

                          Brand Name : Miebo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 12, 2023

                          Lead Product(s) : Perfluorohexyloctane

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalm...

                          Brand Name : Xiidra

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 11, 2023

                          Lead Product(s) : Lifitegrast

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the acquisition, Bausch & Lomb expands its OTC product line by obtaining Blink portfolio of eye drops including, Blink® Tears (polyethylene glycol).

                          Brand Name : Blink® Tears

                          Molecule Type : Small molecule

                          Upfront Cash : $106.5 million

                          July 06, 2023

                          Lead Product(s) : Macrogol

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Recipient : Johnson & Johnson

                          Deal Size : $106.5 million

                          Deal Type : Acquisition

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...

                          Brand Name : Xiidra

                          Molecule Type : Small molecule

                          Upfront Cash : $1,750.0 million

                          June 30, 2023

                          Lead Product(s) : Lifitegrast

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Recipient : Novartis Pharmaceuticals Corporation

                          Deal Size : $2,500.0 million

                          Deal Type : Divestment

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.

                          Brand Name : Miebo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 18, 2023

                          Lead Product(s) : Perfluorohexyloctane

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Novaliq

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the...

                          Brand Name : 37926

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 04, 2023

                          Lead Product(s) : Perfluorohexyloctane

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Novaliq

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Results with Xipere (triamcinolone acetonide) showed statistically significant reduction in tumor growth rate compared to each patient’s documented growth rate at study entry, and an 88.9% tumor control rate.

                          Brand Name : Xipere

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 04, 2022

                          Lead Product(s) : Triamcinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Recipient : Clearside Biomedical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank